Symphogen
About:
Symphogen is a biotechnology company that produces recombinant polyclonal antibody drugs for disease treatment and prevention.
Website: http://www.symphogen.com
Top Investors: Novo Holdings, Takeda Ventures, Danske Bank, Vaekstfonden, Gilde Healthcare
Description:
Symphogen is the leader in developing recombinant polyclonal antibodies (rpAb), a new class of biopharmaceuticals for the treatment or prophylaxis of serious human diseases.
Total Funding Amount:
$375M
Estimated Revenue Range:
$1B to $10B
Headquarters Location:
Lyngby, Hovedstaden, Denmark
Founded Date:
2000-01-01
Contact Email:
info(AT)symphogen.com
Founders:
John Haurum, Kirsten Drejer, Thomas Feldthus
Number of Employees:
101-250
Last Funding Date:
2015-10-22
IPO Status:
Private
© 2025 bioDAO.ai